Test device

Abstract

To perform a test desired by a user by using results of plural times of measurement of biological information in a test device.SOLUTION: A processor obtains a determination result whether first biological information determined on the basis of a monitoring result of the first biological information of a user has an abnormal tendency or not, and presents at least one test candidate for obtaining second biological information related to the first biological information to the user when the determination result has the abnormal tendency. The processor receives specification of at least one item which is an index when the user selects the presented test candidate and presents the test candidate in a display mode in accordance with the specified item.SELECTED DRAWING: Figure 6

Description

Technical Field

[0001] The technology of the present disclosure relates to an inspection apparatus.

Background Art

[0002] In recent years, with the use of wearable terminals such as smartwatches, it has become popular to monitor biological information such as pulse, blood pressure, respiration, electrocardiogram, maximum oxygen uptake, blood glucose equivalent value, and body temperature, and to manage health promotion and disease prevention based on the monitored biological information. In addition, by using big data related to biological information and learning AI (Artificial Intelligence), it is also being carried out to identify diseases and diseases that may be suffered with high accuracy.

[0003] In addition, a method of providing health management information to a user using biological information has been proposed. For example, in Patent Document 1, a method of presenting a recommended action plan such as the content of exercise and diet when an abnormality is found in the blood glucose value monitoring result obtained by a wearable terminal has been proposed.

[0004] On the other hand, an inspection automaton that automatically performs a biological inspection as described in Patent Document 2 has been proposed. The inspection automaton described in Patent Document 2 is provided with an inspection kit removably, and a user collects a specimen such as blood using the inspection kit. Then, when the user sets the specimen in the inspection automaton, the inspection automaton performs an inspection using the specimen and transmits the inspection result to the user's personal computer or mobile terminal. If such an inspection automaton is installed in a company, pharmacy, convenience store, etc., the user can perform an inspection at a desired timing without going to a hospital.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document 2

SUMMARY OF THE INVENTION

PROBLEMS TO BE SOLVED BY THE INVENTION

[0006] Here, in a wearable terminal, although biological information can be monitored, the accuracy of the acquired biological information is low when compared with biological information based on a blood test or the like. In the method described in Patent Document 1 above, only a recommended action plan is presented to the user. For this reason, in the method described in Patent Document 1, when an abnormal tendency is observed in the monitoring result, the current state of the biological information cannot be accurately grasped. Further, the method described in Patent Document 2 is a method in which the user himself / herself performs a specific test using a test kit, and does not perform a test based on biological information acquired in a wearable terminal or the like.

[0007] The present disclosure has been made in view of the above circumstances, and an object thereof is to enable a user to perform a desired test using a monitoring result of biological information.

MEANS FOR SOLVING THE PROBLEMS

[0008] The inspection apparatus according to the present disclosure includes at least one processor, and the processor acquires a determination result as to whether or not first biological information, which is determined based on a monitoring result of a user's first biological information, has an abnormal tendency. When the determination result shows an abnormal tendency, at least one inspection candidate for acquiring second biological information related to the first biological information is presented to the user, at least one item that serves as an index when the user selects the presented inspection candidate is received, and the inspection candidate is presented in a display form corresponding to the designated item.

[0009] In the inspection apparatus according to the present disclosure, the processor presents a question to the user for determining the display position of an inspection candidate on at least one scale according to at least one specified item, determines the display position of the inspection candidate on the scale according to the answer to the question, and presents the inspection candidate to the user in a display form in which an icon representing the inspection candidate is displayed at the determined display position on the scale.

[0010] In the inspection apparatus according to the present disclosure, after displaying an icon representing an inspection candidate, the processor can accept an additional specification of an item by the user, and may update the display form of the icon representing the inspection candidate when the additional specification of the item is made.

[0011] In the inspection apparatus according to the present disclosure, the processor may repeat accepting an additional specification of an item, presenting a question according to the added item, and updating the display mode of the inspection candidate until an inspection candidate is selected by the user.

[0012] In the inspection apparatus according to the present disclosure, the item may include at least one of the cost required for the inspection, the sense of security at the time of collecting the subject, the degree of restraint during the inspection, invasiveness or non-invasiveness, the time required until the inspection result is obtained, whether or not it includes a risk check for various diseases, and the accuracy of the inspection.

[0013] In the inspection apparatus according to the present disclosure, the processor may selectively determine an inspection candidate from a plurality of inspection methods including the specification of the type of the subject and for obtaining second biological information from the subject.

[0014] In the inspection apparatus according to the present disclosure, an inspection candidate for collecting a user's specimen and obtaining second biological information is presented by the processor, and when the inspection candidate is selected, the processor presents guidance for collecting the specimen to the user and obtains second biological information based on the specimen collected by the user.

[0015] In the inspection device according to the present disclosure, the processor may present the second biological information to the user.

[0016] In the inspection device according to the present disclosure, the inspection candidate may include an inspection candidate capable of acquiring the second biological information with higher accuracy than the first biological information.

[0017] In the inspection device according to the present disclosure, the processor may determine the inspection candidate according to the degree of the abnormal tendency.

[0018] In the inspection device according to the present disclosure, the processor may determine the inspection candidate according to the elapsed time from the time when the first biological information is determined to have an abnormal tendency to the current time.

[0019] In the inspection device according to the present disclosure, the processor may determine the inspection candidate according to the risk factors of the user.

[0020] In the inspection device according to the present disclosure, the processor may present the statistical information of the inspection candidates selected in the past to the user.

[0021] In the inspection device according to the present disclosure, the first biological information may be a blood glucose equivalent value having a correlation with the blood glucose level, and the second biological information may include at least one of the blood glucose level and HbA1c.

[0022] In the inspection device according to the present disclosure, the abnormal tendency may be a postprandial hyperglycemia spike.

[0023] In the inspection device according to the present disclosure, the processor may determine the inspection candidate based on the user's diet content.

[0024] In the inspection device according to the present disclosure, the processor may determine the inspection candidate based on the user's meal time.

[0025] In the inspection apparatus according to the present disclosure, the processor may present an inspection candidate including an act of drinking a glucose drink when the elapsed time after a meal based on the meal time has passed a predetermined time.

[0026] In the inspection apparatus according to the present disclosure, the first biological information may be at least one of heartbeat, blood pressure, respiration, electrocardiogram, maximum oxygen uptake, arterial blood oxygen saturation, and body temperature, and the second biological information may be a diagnosis result of the user's illness.

[0027] In the inspection apparatus according to the present disclosure, when the processor obtains a determination result that the first biological information does not tend to be abnormal, the processor may notify the user to that effect.

[0028] In the inspection apparatus according to the present disclosure, the processor may obtain the determination result via wireless communication.

[0029] In the inspection apparatus according to the present disclosure, the determination result is derived by a measuring device worn by the user, and the processor may obtain the determination result from the measuring device.

[0030] In the inspection apparatus according to the present disclosure, the first biological information is measured a plurality of times by a measuring device worn by the user, and the processor obtains a plurality of measurement results of the first biological information from the measuring device, and based on the plurality of measurement results of the first biological information obtained, determines whether the first biological information has an abnormal tendency and obtains a determination result.

[0031] In this case, the measuring device may be wearable.

[0032] In the inspection apparatus according to the present disclosure, when it is impossible to determine whether the first biological information has an abnormal tendency, the processor may notify the user to increase the wearing time of the measuring device.

[0033] In the inspection apparatus according to the present disclosure, the processor may acquire second biological information and determine whether to continue measuring the first biological information according to the acquired second biological information.

[0034] In the inspection apparatus according to the present disclosure, after presenting guidance according to a selected inspection candidate to the user, the processor may further present guidance according to another inspection candidate for performing an inspection that steps up from the selected inspection candidate.

Advantages of the Invention

[0035] According to the present disclosure, the user can perform an inspection according to measurement results of biological information multiple times.

Brief Description of the Drawings

[0036]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Figure 12

Figure 13

Figure 14

Figure 15

Figure 16

Figure 17

Figure 18

Figure 19

Figure 20

Figure 21

Figure 22

Figure 23

Figure 24

Figure 25

Figure 26

Figure 27

Figure 28

Figure 29

Figure 30

Figure 31

Figure 32

Figure 33

Figure 34

Figure 35

Figure 36

Figure 37

Mode for Carrying Out the Invention

[0037] [First Embodiment]

[0038] Hereinafter, the first embodiment of the present disclosure will be described with reference to the drawings. FIG. 1 is a schematic diagram showing the configuration of a test support system to which the test device according to the first embodiment of the present disclosure is applied. As shown in FIG. 1, the test support system 10 includes the test device 1 according to the present embodiment, a mobile terminal 2 such as a smartphone, and measuring instruments 3 and 4. The mobile terminal 2 and the measuring instruments 3 and 4 are capable of communicating with each other by short-range wireless such as Bluetooth (registered trademark). Also, the test device 1 and the measuring instruments 3 and 4 are also capable of communicating by short-range wireless. Further, the test device 1 and the mobile terminal 2 are also capable of communicating by short-range wireless. The test device 1 is connected in a communicable state with a test server 6 via a wired or wireless network 5.

[0039] The inspection device 1 is installed in places where people gather, such as convenience stores, shopping malls, stations, airports, companies, pharmacies, community centers, elderly care plazas, and hot spring facilities. Alternatively, the inspection device 1 is mounted on a mobile vehicle and moved to a desired location for use. The inspection device 1 determines whether the user's blood glucose equivalent value has an abnormal tendency based on the monitoring results of the blood glucose equivalent value transmitted from a measuring device 3 or the like as described later by the user, and presents the user with an inspection candidate for acquiring biological information related to the blood glucose equivalent value according to the determination result. In addition, the inspection device 1 presents the user with guidance according to the inspection candidate selected by the user to assist the user in performing the inspection. Note that the blood glucose equivalent value is biological information that has a correlation with the blood glucose value and is measured by a method that does not require blood sampling. In addition, the inspection device 1 shown in FIG. 1 shows an analysis device 18 and a storage case 20 described later.

[0040] The measuring device 3 is a wearable terminal of a wristwatch type such as a smartwatch and has a function of monitoring a blood glucose equivalent value that has a correlation with the user's blood glucose value. Monitoring means automatically measuring the blood glucose equivalent value constantly at a predetermined time interval, such as every 15 minutes or 30 minutes, without the user giving an instruction to measure. Note that the measuring device 3 may measure the blood glucose equivalent value even when there is an instruction from the user while constantly measuring the blood glucose equivalent value. In addition, the measuring device 3 may be of a type that is worn on the user only during measurement, such as a finger clip.

[0041] In addition, the measuring device 3 is a non-invasive blood glucose equivalent value measuring device, and for example, analyzes a signal emitted by glucose in the blood by irradiating the user with infrared rays to derive the blood glucose equivalent value. Alternatively, the user's electrocardiogram is measured, and a blood glucose equivalent value correlated with the change in the electrocardiogram is derived. The measuring device 3 transmits the derived blood glucose equivalent value to the inspection device 1.

[0042] The measuring device 4 is a device for measuring an invasive blood glucose equivalent value. For example, the measuring device 4 is worn by the user and monitors the glucose concentration in the interstitial fluid under the user's epidermis, and transmits the measured glucose concentration to the inspection device 1. For this purpose, the measuring device 4 has a needle-shaped filament 4A that is inserted under the user's epidermis. Since the glucose concentration is correlated with the blood glucose value, it becomes a blood glucose equivalent value.

[0043] The blood glucose equivalent value measured by the measuring devices 3 and 4 is an example of the first biological information. Note that the user only needs to have either one of the measuring devices 3 and 4.

[0044] Here, in the present embodiment, the inspection device 1 determines whether the blood glucose equivalent value has an abnormal tendency based on the monitoring result of the blood glucose equivalent value. In the present embodiment, as an abnormal tendency of the blood glucose equivalent value, it is determined whether the user is in a state of postprandial hyperglycemia spike. Postprandial hyperglycemia spike is a symptom found in the early stage of diabetes, in which even if the fasting blood glucose value is within the normal range, the blood glucose value approximately 1 to 2 hours after a meal rises significantly. If postprandial hyperglycemia spike is left untreated, blood vessels are damaged, and arteriosclerosis and diabetic complications are likely to progress. It is also considered that complications such as myocardial infarction, angina pectoris, and stroke are likely to progress. The present embodiment monitors the blood glucose equivalent value, and when it is determined that the blood glucose equivalent value has an abnormal tendency, it presents the user with a recommended test candidate for the user, so that the user can undergo a test that can obtain biological information for accurately grasping postprandial hyperglycemia spike.

[0045] The network 5 is a wide area network (wide area communication network WAN: Wide Area Network) that widely connects the inspection device 1 and the inspection server 6 via a public line network or a dedicated line network.

[0046] The inspection server 6 is installed in an inspection center that supports inspections related to blood glucose levels. The inspection server 6 has a function of providing the inspection program according to this embodiment to the inspection device 1 and providing the information necessary when the inspection device 1 executes the inspection program to the inspection device 1. The inspection server 6 is a general-purpose computer installed with a software program that provides server functions.

[0047] The inspection center provides various supports for the user regarding the inspection related to blood glucose levels. For example, by providing the inspection program according to this embodiment, it supports the user in selecting an inspection method. Also, when the user selects an inspection method, it supports the purchase of the equipment and inspection kits necessary for the selected inspection and supports the reservation of hospital inspections. In addition, it also performs inspections using specimens self-collected by the user and delivered from the user. The inspection center is an example of an external inspection institution.

[0048] Next, the inspection device according to this embodiment will be described. First, with reference to FIG. 2, the hardware configuration of the inspection device according to this embodiment will be described. As shown in FIG. 2, the inspection device 1, which is the inspection device according to this embodiment, includes a CPU (Central Processing Unit) 11, a non-volatile storage 13, and a memory 16 as a temporary storage area. Further, the inspection device 1 includes a touch panel 14, a communication I / F (InterFace) 15 for performing short-range wireless communication, and a network I / F 17 wirelessly connected to the network 5. The inspection device 1 also includes an analysis device 18. Furthermore, the inspection device 1 includes a housing case 20. The CPU 11, the storage 13, the touch panel 14, the communication I / F 15, the memory 16, the network I / F 17, and the analysis device 18 are connected to a bus 19. Note that the CPU 11 is an example of the processor in the present disclosure.

[0049] Storage 13 is realized by an SSD (Solid State Drive), flash memory, or the like. The inspection program 12 installed in the inspection device 1 is stored in the storage 13 as a storage medium. The CPU 11 reads the inspection program 12 from the storage 13, expands it in the memory 16, and executes the expanded inspection program 12.

[0050] The touch panel 14 is composed of a liquid crystal display, an organic EL, etc., and performs various displays related to the processing performed by the inspection device 1. The touch panel 14 also has a function as an input device for performing various inputs to the inspection device 1.

[0051] Note that the inspection program 12 is stored in a state where it can be externally accessed by the inspection server 6, and is downloaded and installed in the inspection device 1 in response to a request.

[0052] The analysis device 18 derives biological information such as blood glucose level and HbA1c (hemoglobin A1c) by analyzing the user's blood. For this purpose, the analysis device 18 has a mechanism for collecting the user's blood and a mechanism for obtaining blood from a test kit described later.

[0053] A plurality of test kits 20A for calculating the user's blood are stored in the storage case 20. The test kit 20A includes, in addition to a blood collection instrument, a glucose drink for the user to drink before the test. When the user selects a test that requires self-blood collection as described later, the user can take out the test kit from the storage case, drink the glucose drink if necessary, and then perform self-blood collection using the blood collection instrument.

[0054] Next, the mobile terminal 2 will be described. FIG. 3 is a hardware configuration diagram of the mobile terminal 2. As shown in FIG. 3, the mobile terminal 2 is a portable computer such as a smartphone, and includes a CPU 21, a non-volatile storage 23, and a memory 26 as a temporary storage area. Further, the mobile terminal 2 includes a touch panel 24, a communication I / F (InterFace) 25 for performing short-range wireless communication, and a network I / F 27 wirelessly connected to the network 5. Further, the mobile terminal 2 includes a camera 28. The CPU 21, the storage 23, the touch panel 24, the communication I / F 25, the memory 26, the network I / F 27, and the camera 28 are connected to a bus 29.

[0055] The storage 23 is realized by an SSD (Solid State Drive), a flash memory, or the like. The analysis program 22 installed in the mobile terminal 2 is stored in the storage 23 as a storage medium. The CPU 21 reads the analysis program 22 from the storage 23, expands it in the memory 26, and executes the expanded analysis program 22.

[0056] The touch panel 24 is composed of a liquid crystal display, an organic EL, or the like, and performs various displays related to the processing performed by the mobile terminal 2. Further, the touch panel 24 also has a function as an input device for performing various inputs to the mobile terminal 2.

[0057] The camera 28 takes a picture of the user's meal, for example, according to the user's instruction, thereby acquiring an image of the meal. The acquired meal image is stored in the storage 23. Alternatively, it is transmitted to the inspection device 1 together with the monitoring result of the blood glucose equivalent value or the like as described later, according to the user's instruction or without waiting for the instruction.

[0058] Note that the analysis program 22 is stored in the inspection server 6 in a state accessible from the outside, downloaded to the mobile terminal 2 in response to a request, and installed. The analysis program 22 analyzes the monitoring results of the blood glucose equivalent values transmitted from the measuring instruments 3 and 4 to determine whether the blood glucose equivalent values tend to be abnormal. Note that the analysis program 22 may only execute the process of storing the blood glucose equivalent values transmitted from the measuring instruments 3 and 4 in the storage 23. When the monitoring results of the blood glucose equivalent values are transmitted from the measuring instruments 3 and 4 to the inspection device 1, the mobile terminal 2 is not used.

[0059] Also, in this embodiment, it is assumed that the user has completed user registration with the inspection center. By performing authentication on the inspection device 1, the user can transmit the monitoring results of the blood glucose equivalent values to the inspection device 1 or perform an inspection on the inspection device 1.

[0060] Next, the measuring instrument will be described. FIG. 4 illustrates the hardware configuration of the measuring instrument 3. The measuring instrument 3 is a wristwatch-type computer and includes a CPU 31, a non-volatile storage 33, and a memory 36 as a temporary storage area, as shown in FIG. 4. The measuring instrument 3 also includes a touch panel 34, a communication I / F 35 for performing short-range wireless communication, a network I / F 37 wirelessly connected to an external network (not shown), and a sensor 38. The CPU 31, the storage 33, the touch panel 34, the communication I / F 35, the memory 36, the network I / F 37, and the sensor 38 are connected to a bus 39.

[0061] The storage 33 is realized by an SSD, a flash memory, or the like. The storage 33 as a storage medium stores a measurement program 32 for measuring the blood glucose equivalent value installed in the measuring instrument 3. The CPU 31 reads the measurement program 32 from the storage 33, expands it in the memory 36, and executes the expanded measurement program 32.

[0062] The touch panel 34 is composed of a liquid crystal display, an organic EL, etc., and performs various displays related to the processing performed by the measuring device 3. The touch panel 34 also has a function as an input device for performing various inputs to the measuring device 3.

[0063] The sensor 38 is composed of, for example, an infrared light source and an infrared detector, irradiates infrared rays to the user wearing the measuring device 3, and detects a signal emitted by glucose in the blood. The signal detected by the sensor 38 is analyzed by the CPU 31 that executes the measurement program 32, and a blood glucose equivalent value is derived. The sensor 38 may also measure an electrocardiogram. In this case, the electrocardiogram is analyzed by the measurement program 32, and a blood glucose equivalent value is derived.

[0064] Note that the measurement program 32 is stored in a state where it can be externally accessed by the inspection server 6, and is downloaded and installed in the measuring device 3 in response to a request. Alternatively, the measurement program 32 is downloaded to the inspection device 1 or the mobile terminal 2, and is downloaded and installed in the measuring device 3 via short-range wireless communication with the inspection device 1 or the mobile terminal 2.

[0065] In the measuring device 3, the sensor 38 detects a signal emitted by glucose in the blood at a predetermined time interval. The CPU 31 analyzes the signal by executing the measurement program 32 and derives a blood glucose equivalent value. Further, the CPU 31 stores the derived blood glucose equivalent value in the storage 33 in association with the measurement time. The blood glucose equivalent value associated with the measurement time becomes the monitoring result of the blood glucose equivalent value. Then, when the user uses the inspection device 1, the CPU 31 transmits the monitoring result of the blood glucose equivalent value from the communication I / F 35 to the inspection device 1 according to the user's instruction or without waiting for the user's instruction.

[0066] Next, the measuring device 4 will be described. FIG. 5 is a hardware configuration diagram of the measuring device 4. As shown in FIG. 5, the measuring device 4 is a device that is worn on the human body and measures the glucose concentration in the interstitial fluid under the epidermis as a blood glucose equivalent value, for example, as described in Japanese Patent Application Laid-Open No. 2016-520379. The measuring device 4 includes a processor 41, a memory 42 as a temporary storage area, a communication I / F 43 that performs short-range wireless communication, and a sensor 44. A needle-like filament 4A that is inserted under the epidermis is connected to the sensor 44. The processor 41, the memory 42, the communication I / F 43, and the sensor 44 are composed of an application specific integrated circuit (ASIC) 45 for the purpose of measuring glucose in the interstitial fluid.

[0067] In the measuring device 4, the sensor 44 detects a signal representing the glucose concentration in the interstitial fluid under the epidermis at a predetermined time interval or according to a measurement instruction by the user. The processor 41 analyzes the signal to derive the glucose concentration. Further, the processor 41 stores the derived glucose concentration in the memory 42 in association with the measurement time. The blood glucose equivalent value associated with the measurement time becomes the monitoring result of the blood glucose equivalent value. Then, when the user uses the inspection device 1, the processor 41 transmits the monitoring result of the blood glucose equivalent value from the communication I / F 43 to the inspection device 1 according to the user's instruction or without waiting for the user's instruction.

[0068] Next, the functional configuration of the inspection device according to the present embodiment will be described. FIG. 6 is a diagram showing the functional configuration of the inspection device according to the present embodiment. As shown in FIG. 6, the inspection device 1 includes an acquisition unit 51, a determination unit 52, a decision unit 53, and a presentation unit 54. Then, the CPU 11 functions as the acquisition unit 51, the determination unit 52, the decision unit 53, and the presentation unit 54 by executing the inspection program 12. In the following description, it is assumed that the user has the measuring device 3, and the inspection device 1 directly acquires the monitoring result of the blood glucose equivalent value from the measuring device 3.

[0069] The acquisition unit 51 acquires the monitoring result of the blood glucose equivalent value transmitted from the communication I / F 35 of the measuring device 3 by receiving it through the communication I / F 15. In this embodiment, for example, the monitoring result of the blood glucose equivalent value measured in the most recent 24 hours is acquired.

[0070] The determination unit 52 determines whether the blood glucose equivalent value has an abnormal tendency based on the monitoring result of the blood glucose equivalent value acquired by the acquisition unit 51. Specifically, the determination unit 52 determines whether the blood glucose equivalent value has a tendency of postprandial hyperglycemia spike.

[0071] Here, postprandial hyperglycemia will be described. FIG. 7 is a diagram showing the daily blood glucose variation of a type 2 diabetic patient. In FIG. 7, the horizontal axis represents the time of a day (24 hours), and the vertical axis represents the blood glucose value (mg / dL). The solid line indicates the blood glucose value of patients with HbA1c (hemoglobin A1c) of 9% or more. The dashed line indicates the blood glucose value of patients with HbA1c less than 7 - 8%. The dash-dotted line indicates the blood glucose value of patients with HbA1c of 6.5% - less than 7%. Also, in FIG. 7, the blood glucose value variation when having breakfast at around 8 o'clock, lunch at around 12 o'clock, and dinner at around 19 o'clock is shown. Note that HbA1c is the one in which glucose is bound to hemoglobin, which is an erythrocyte component in the blood. HbA1c represents the blood glucose variation in 1 - 2 months.

[0072] As shown in FIG. 7, regardless of the value of HbA1c, an increase in blood glucose value is seen after meals. However, the larger the HbA1c, the more prominent the postprandial hyperglycemia spike in which the blood glucose value increases significantly, especially after breakfast. To make the postprandial hyperglycemia spike after breakfast clearer, a line is provided at the 8 o'clock position in FIG. 7.

[0073] Also, the user may transmit the most recent meal time from the measuring device 3 to the inspection device 1. Or, the meal time may be input from the touch panel 14 of the inspection device 1. Alternatively, the user may take a picture of the meal with the camera 28 of the mobile terminal 2 and transmit the taken image of the meal to the inspection device 1. In this case, the information of the shooting date and time included in the header information of the taken image of the meal can be used as the meal time.

[0074] When, in the monitoring result of the blood glucose equivalent value transmitted from the measuring device 3, there is a situation where the time variation of the blood glucose equivalent value is equal to or greater than a predetermined threshold Th1 after a meal, the determination unit 52 determines that the blood glucose equivalent value has an abnormal tendency. In the present embodiment, the time variation is, for example, the variation of the blood glucose value per hour.

[0075] In the present embodiment, the determination unit 52 further determines whether or not there is a situation where the variation of the blood glucose equivalent value is equal to or greater than a threshold Th2. If the determination is affirmative, it is determined that the postprandial hyperglycemia spike is large. Note that Th2 > Th1. Further, when the determination is negative, the determination unit 52 determines that the postprandial hyperglycemia spike is small.

[0076] When the determination unit 52 determines that the blood glucose equivalent value does not have an abnormal tendency, it notifies to that effect. The notification will be described later.

[0077] When the determination unit 52 determines that the blood glucose equivalent value has an abnormal tendency, the decision unit 53 determines the test candidates to be recommended to the user. Further, the decision unit 53 determines the test candidates according to the degree of the abnormal tendency.

[0078] FIG. 8 is a table showing test methods for biological information related to the blood glucose equivalent value. In FIG. 8, for four types of test methods (1) to (4), the test method, the measured biological information, the cost, and the required time are shown as test information. The test methods (1) to (4) are all test methods that require the user to have their blood drawn.

[0079] The inspection method (1) is an inspection method that measures only blood glucose levels. The inspection method (2) is an inspection method that performs several inspections in addition to blood glucose levels. In FIG. 8, several inspection methods are indicated by “+α”. The inspection method (3) is an inspection method that inspects blood glucose levels, HbA1c, and multiple other items. The inspection method (4) is an inspection method that measures only HbA1c. In FIG. 8, multiple items other than blood glucose levels and HbA1c are indicated by “+other multiple items”. Note that the inspection methods (1), (2), and (4) can be executed by the analysis device 18 of the inspection device 1, and in that case, inspection results can be obtained in a relatively short time. The obtained inspection results are displayed on the touch panel 14. The inspection method (3) is an inspection that involves delivering a specimen to an external inspection institution, i.e., an inspection center.

[0080] Blood glucose levels, HbA1c, and other biological information, which are biological information obtained by the inspection methods (1) to (4), are an example of the second biological information.

[0081] Also, FIG. 8 shows various items that serve as indicators when the user selects the presented inspection candidates. Specifically, the items of the cost required for the inspection (cost), the time required until the inspection results are obtained (required time), whether or not it includes a risk check for various diseases (risk check), and the accuracy of the inspection (accuracy) are shown. In each item column, the degree of preference is shown for each inspection method. The degree of preference is represented by the symbols A, B, C, and D in descending order of preference. A represents very preferable, B represents preferable, C represents neither, and D represents not preferable.

[0082] Regarding the cost, the lower the cost, the greater the degree of preference. Regarding the required time, the shorter the time, the greater the degree of preference. Regarding the risk check for various diseases, the degree of preference increases when the number of inspection items is large and the inspection includes diseases other than diabetes. Regarding the accuracy, the higher the accuracy of detecting postprandial hyperglycemia in particular, the greater the degree of preference.

[0083] In addition to cost, required time, risk check, and accuracy, items may also include the sense of comfort during the collection of the subject, the degree of restraint during the examination, and whether it is invasive or non-invasive. Regarding the sense of comfort, the smaller the user's anxiety about the collection of the subject (for example, blood collection), the greater it is. For example, when the examination method is blood collection in a hospital, blood collection by medical staff provides a high sense of comfort for the user. Regarding the degree of restraint, the degree of preference varies depending on the presence or absence of going out and the waiting time, and the degree is greater when there is no going out and the waiting time is short. Regarding invasiveness, the degree of preference is greater when the sample can be obtained without pain. For example, when the examination method is a glucose tolerance test, since blood collection needs to be performed three times after glucose loading, the degree of preference regarding invasiveness is poor.

[0084] Also, FIG. 8 shows various abnormal tendencies of blood glucose equivalent values. Specifically, it shows that the postprandial hyperglycemia spike is large and that the postprandial hyperglycemia spike is small.

[0085] Also, in FIG. 8, for each of the abnormal tendencies, a ○ is given in the column of the test method to be a test candidate. That is, when the postprandial hyperglycemia spike is large, a ○ is given to the test methods (1) to (3). Note that for the test methods (1) to (3), postprandial blood collection is essential for the determination of the postprandial hyperglycemia spike. When the postprandial hyperglycemia spike is small, a ○ is given to all the test methods (1) to (4).

[0086] In this embodiment, the table shown in FIG. 8 is stored in the storage 13 as a table. The determination unit 53 refers to the table stored in the storage 13 and determines inspection candidates according to the abnormal tendency of the blood glucose equivalent value determined by the determination unit 52. Specifically, when the abnormal tendency determined by the determination unit 52 is a large postprandial hyperglycemia spike, the determination unit 53 refers to the table and determines the inspection methods (1) to (3) as inspection candidates. When the abnormal tendency determined by the determination unit 52 is a small postprandial hyperglycemia spike, the determination unit 53 determines the inspection methods (1) to (4) as inspection candidates. Note that any of the inspection methods (1) to (4) can be used to collect blood samples in the inspection apparatus 1, and it is also possible to deliver the collected specimens to the inspection center for inspection. On the other hand, for the inspection method (3), it is necessary to deliver the specimen to the inspection center, which is an external inspection institution, for inspection.

[0087] The presentation unit 54 presents the inspection candidates determined by the determination unit 53 to the user. In this embodiment, the presentation unit 54 presents the inspection candidates to the user by displaying the inspection candidates determined by the determination unit 53 on the touch panel 14.

[0088] Hereinafter, the processing performed in this embodiment will be described. FIGS. 9 and 10 are flowcharts showing the processing performed in this embodiment. In order to determine the abnormal tendency of the blood glucose equivalent value, the acquisition unit 51 monitors whether the communication I / F 15 has received the monitoring result of the blood glucose equivalent value transmitted from the measuring device 3 (step ST1). When step ST1 is affirmed, the determination unit 52 determines whether the blood glucose equivalent value has an abnormal tendency based on the monitoring result of the blood glucose equivalent value (step ST2). When step ST2 is negated, the determination unit 52 notifies that the blood glucose equivalent value does not have an abnormal tendency (step ST3) and returns to step ST1. FIG. 11 is a diagram showing a notification screen when the blood glucose equivalent value does not have an abnormal tendency. As shown in FIG. 11, a notification 61 of "The blood glucose level does not show an abnormal tendency. Please continue with your current lifestyle." is displayed on the notification screen 60.

[0089] When step ST2 is affirmed, the determination unit 52 determines the degree of the abnormal tendency of the equivalent blood glucose value. First, based on the monitoring result of the equivalent blood glucose value, the determination unit 52 determines whether there has been a situation where the fluctuation of the equivalent blood glucose value is equal to or greater than the threshold Th2 (step ST4). When step ST4 is affirmed, the decision unit 53 determines, as the inspection candidate, the inspection method for the case of a large postprandial hyperglycemia spike among the inspection methods included in the table shown in FIG. 8 (step ST5). When step ST4 is negated, the decision unit 53 determines, as the inspection candidate, the inspection method for the case of a small postprandial hyperglycemia spike among the inspection methods included in the table shown in FIG. 8 (step ST6).

[0090] Subsequent to steps ST5 and ST6, the determination unit 52 determines whether the current time is within 2 hours after a meal based on the meal time (step ST7). When step ST7 is affirmed, the presentation unit 54 presents the determined inspection candidate to the user without adding the requirement to drink a glucose drink for the inspection candidate (no drink addition; step ST8) (step ST10). On the other hand, when step ST7 is negated, the presentation unit 54 adds the requirement to drink a glucose drink for the inspection candidate (drink addition; step ST9) and presents the determined inspection candidate to the user (step ST10).

[0091] FIG. 12 is a diagram showing a screen for presenting inspection candidates. As shown in FIG. 12, on the inspection candidate presentation screen 62, inspection candidates 63 for the case of a large postprandial hyperglycemia spike and including a drink are displayed. That is, for each of "blood glucose level only" in inspection method (1), "blood glucose level + α" in inspection method (2), and "blood glucose level + HbA1c + other multiple items" in inspection method (3), a total of six inspection candidates for the inspection with a drink and delivering the blood collection container later are displayed. For the case with a drink, it is displayed as "Drink &", and for the inspection with the blood collection container delivered later, it is displayed as "Blood collection container delivery &". Further, the presentation screen 62 includes a statistical information reference button 64, an item selection button 65, and a determination button 66. The statistical information reference button 64 is for displaying statistical information as will be described later. The item selection button 65 is for displaying a list screen of items that serve as indicators when the user selects inspection candidates as will be described later. The determination button 66 is for determining the inspection candidates.

[0092] Note that FIG. 13 shows a presentation screen 62A for inspection candidates in the case of a large postprandial hyperglycemia spike and not including a drink. FIG. 14 shows a presentation screen 62B for inspection candidates in the case of a small postprandial hyperglycemia spike and including a drink. FIG. 15 shows a presentation screen 62C for inspection candidates in the case of a small postprandial hyperglycemia spike and not including a drink. On the presentation screen 62A shown in FIG. 13, inspection candidates 63A for the case of a large postprandial hyperglycemia spike and not including a drink are displayed. On the presentation screen 62B shown in FIG. 14, inspection candidates 63B for the case of a small postprandial hyperglycemia spike and including a drink are displayed. On the presentation screen 62C shown in FIG. 15, inspection candidates 63C for the case of a small postprandial hyperglycemia spike and not including a drink are displayed. Note that when the postprandial hyperglycemia spike is small, "blood glucose level only" in inspection method (1), "blood glucose level + α" in inspection method (2), "blood glucose level + HbA1c + other multiple items" in inspection method (3), and "HbA1c only" in inspection method (4) are selected as inspection candidates. In the following description, it will be described as if the presentation screen 62 shown in FIG. 12 is displayed.

[0093] Each test candidate included in the test candidates 63 is selectable. When the user selects a test candidate included in the test candidates, the content description of the selected test candidate is displayed. For example, when the user selects "drink & blood glucose only" from among the six test candidates, as shown in FIG. 16, an explanation 67 of "This is a test in which blood is drawn 60 minutes after drinking a glucose drink." is displayed between the item selection button 65 and the determination button 66. When the user selects the determination button 66 in this state, the selected test candidate is determined as the test method to be performed by the user. The processing after the test method is determined will be described later.

[0094] Also, when the user selects the statistical information reference button 64, the statistical information of the test candidates selected in the past is displayed. Here, a plurality of test candidates are selected according to the abnormal tendency of the user's blood glucose equivalent value and presented to the user, and the user selects one test candidate from among the plurality of test candidates to perform the test. The statistical information represents the ratio selected in the past by the current user performing the test and / or other users for each of the plurality of test candidates. Note that the statistical information is derived by tabulating which test candidates were selected in the past for test candidates having an abnormal tendency similar to the abnormal tendency of the user's blood glucose equivalent value. For example, if the abnormal tendency of the user's blood glucose equivalent value is a large postprandial hyperglycemia spike, the statistical information for the six presented test candidates is displayed.

[0095] FIG. 17 is a diagram showing a presentation screen of test candidates on which the statistical information of the test candidates is displayed. As shown in FIG. 17, the statistical information 68 for each of the six presented test candidates is displayed between the item selection button 65 and the determination button 66. As shown in FIG. 17, in the statistical information 68, the ratio of each test candidate selected in the past is shown as a percentage. Note that the statistical information 68 is stored in the test server 6, and when the statistical information reference button 64 is selected, the mobile terminal 2 accesses the test server 6 to acquire the statistical information 68 and presents it to the user.

[0096] Even when the statistical information 68 is displayed, if the user selects any inspection candidate and then selects the decision button 66, the selected inspection candidate is determined as the inspection method to be performed by the user.

[0097] After presenting the inspection candidates, the determination unit 53 determines whether the decision button 66 has been selected (step ST11). If step ST11 is affirmed, the process proceeds to the process of step ST19 described later. If step ST11 is negated, the determination unit 53 determines whether the item selection button 65 has been selected (item selection; step ST12). If step ST12 is negated, the process returns to step ST10. If step ST12 is affirmed, the presentation unit 54 displays a list of items (step ST13).

[0098] FIG. 18 is a diagram showing a list screen for displaying a list of items. As shown in FIG. 18, on the item list screen 70, the text "Which item do you prioritize?" is displayed. Also, on the list screen 70, as items that serve as indicators when selecting inspection candidates, the cost required for the inspection, the time required until the inspection results are obtained, inclusion of risk checks for various diseases, and the accuracy of the inspection are displayed. In addition, a checkbox 71 is provided for each item. The user specifies an item by checking the checkbox of any item that the user wants to prioritize when selecting inspection information, and then selects the item specification button 72. For this purpose, the determination unit 53 determines whether the item specification button 72 has been selected (step ST14). If step ST14 is negated, the process returns to step ST13. If step ST14 is affirmed, the determination unit 53 presents a question to the user for determining the display position of the inspection candidate on the scale described later according to the specified item (step ST15).

[0099] FIG. 19 is a diagram showing a question presentation screen. For the sake of explanation, here, it is assumed that the user selects "the time required until the test results are obtained" as an item serving as an index when selecting test candidates. As shown in FIG. 19, two questions Q1 and Q2 are displayed on the question presentation screen 75. Question Q1 is "If you drink a drink, will you drink it now?", and question Q2 is "If you collect blood at home, when can you receive the blood collection container?". For question Q1, the user answers YES or NO. For question Q2, the user inputs the date and time when the blood collection container can be received in the input box 76. Here, it is assumed that the user answers YES to question Q1 and inputs the date of tomorrow for question Q2.

[0100] When the user selects the answer completion button 77 after answering, the determination unit 53 determines the display position of the test candidates on the scale according to the specified item. Then, the presentation unit 54 presents the test candidates to the user in a display form in which an icon representing the test candidates is displayed at the determined display position on the scale (test candidate scale presentation; step ST16). Here, in the present embodiment, "the time required until the test results are obtained" is selected as an item serving as an index when selecting test candidates. For this reason, the determination unit 53 derives the time required until the test results are obtained according to the answer to the question, and determines the display position of the test candidates on the scale representing the required time. Then, the presentation unit 54 presents the test candidates to the user in a display form in which the icons of the test candidates are displayed at the determined display positions on the scale.

[0101] FIG. 20 is a diagram showing a presentation screen that presents inspection candidates to the user in a display form in which icons of inspection candidates are displayed on a scale. As shown in FIG. 20, a scale 79 representing the required time is displayed on the presentation screen 78, and icons 80A to 80F of six inspection candidates are arranged and displayed along the scale 79 according to the required time. As shown in FIG. 20, the display position of the icon 80A of the inspection candidate corresponding to "drink & blood glucose only" on the scale 79 is "65 minutes later". This is because an answer to drink now is given to question Q1, blood sampling is performed 60 minutes later, and the result is obtained 5 minutes after the start of the inspection. Also, the display position of the icon 80B of the inspection candidate corresponding to "drink & blood glucose + α" on the scale 79 is "75 minutes later". This is because an answer to drink now is given to question Q1, blood sampling is performed 60 minutes later, and the result is obtained 15 minutes after the start of the inspection. Also, the display position of the icon 80C of the inspection candidate corresponding to "drink & blood glucose + HbA1c + other multiple items" on the scale 79 is "3 days later". This is because an answer to drink now is given to question Q1, but it takes 3 days until all the inspection results are obtained.

[0102] The display positions of the icon 80D of the inspection candidate corresponding to "blood collection container arrival & blood glucose only" and the icon 80E of the inspection candidate corresponding to "blood collection container arrival & blood glucose + α" on the scale 79 are "tomorrow". This is because an answer to deliver the blood collection container tomorrow is given to question Q2. The display position of the icon 80F of the inspection candidate corresponding to "blood collection container arrival & blood glucose + HbA1c + other multiple items" on the scale 79 is "4 days later". This is because an answer to deliver the blood collection container tomorrow is given to question Q2, and it takes another 3 days until all the inspection results are obtained.

[0103] Incidentally, if the user is in a situation within 2 hours after a meal and the presentation screen 62A shown in FIG. 13 is displayed, and there is a question as to whether to collect blood immediately as a question item, and if the answer to this question is YES, the presentation screen of the test candidates is shown in FIG. 21. Although the test candidate 63A in the presentation screen 62A shown in FIG. 13 does not indicate that there is no drink, the icon shown in FIG. 21 indicates that there is no drink. In the presentation screen 78A shown in FIG. 21, the display position on the scale 79 of the test candidate icon 80G corresponding to "no drink & blood glucose only" is "after 5 minutes". This is because the result will be available 5 minutes after the start of the test. Also, the display position on the scale 79 of the test candidate icon 80H corresponding to "no drink & blood glucose + α" is "after 15 minutes". This is because the result will be available 15 minutes after the start of the test. Also, the display position on the scale 79 of the test candidate icon 80I corresponding to "no drink & blood glucose + HbA1c + other multiple items" is "after 3 days". This is because it takes 3 days until all test results are available.

[0104] The user can recognize at a glance the required date and time for the presented test candidates from the presentation screen 78. As a result, it is possible to easily compare the test candidates according to the items that the user values.

[0105] The user can determine the test method desired by the user by selecting the test candidate icon on the presentation screen 78 and selecting the decision button 81. Also, by selecting the item selection button 82, it is possible to additionally specify the item that serves as an index when selecting a test candidate. For this purpose, the determination unit 53 determines whether the item selection button 82 has been selected following step ST16 (step ST17). If step ST17 is affirmed, the process returns to step ST13, and the processes of steps ST13 to ST17 are repeated. If step ST17 is negated, the determination unit 53 determines whether the decision button 81 has been selected (step ST18). If step ST18 is affirmed, the process proceeds to the process of step ST19 described later. If step ST18 is negated, the process returns to the process of step ST16.

[0106] Figure 22 is a diagram showing a list screen of items displayed for the second time when step ST17 is affirmed. As shown in Figure 22, among the check boxes 71 displayed on the item list screen 70, the check box for "the time required until inspection results are obtained" has already been checked. The user can further select items on the item list screen 70. Here, assume that the user further selects "the cost required for inspection". The determination unit 53 presents a question to the user for determining the display position of the inspection candidates on the scale according to "the cost required for inspection".

[0107] Figure 23 is a diagram showing a question presentation screen regarding "the cost required for inspection". As shown in Figure 23, one question Q3 is presented on the question presentation screen 84. The question Q3 is "Do you order a drink?". The user answers the question with YES or NO. Here, assume that the user answers YES. After the answer, when the user selects the answer end button 85, the presentation unit 54 updates the display form of the icon representing the inspection candidates. That is, the determination unit 53 determines the display position of the inspection candidates on an additional scale according to the additionally specified item, and the presentation unit 54 presents the inspection candidates to the user in a display form where the icon representing the inspection candidates is displayed at the determined display positions on the presented scale and the additional scale.

[0108] Specifically, the determination unit 53 derives the cost required for inspection according to the answer to the question and determines the display position of the inspection candidates on the scale representing the cost required for inspection. Then, the presentation unit 54 displays the scale of the required time and the scale of the cost required for inspection orthogonally, and presents the inspection candidates to the user by displaying the icons of the inspection candidates at the positions on the two orthogonal scales.

[0109] FIG. 24 is a diagram showing a presentation screen that presents inspection candidates to a user in a display form in which icons of inspection candidates are displayed on a scale when two items are selected. As shown in FIG. 24, on the presentation screen 86, a scale 87 representing cost is displayed orthogonal to a scale 79 representing required time, and icons 80A to 80F of six inspection candidates are arranged and displayed two-dimensionally according to the required time and cost. As shown in FIG. 24, the display position of the icon 80A of the inspection candidate corresponding to "drink & blood glucose level only" on the scale 79 is "after 65 minutes", and the display position on the scale 87 is 600 yen. The cost is the sum of the inspection cost of the blood glucose level only and the price of the glucose drink.

[0110] Also, the display position of the icon 80B of the inspection candidate corresponding to "drink & blood glucose level + α" on the scale 79 is "after 75 minutes", and the display position on the scale 87 is 2300 yen. The cost is the sum of the inspection cost of the blood glucose level + α and the price of the glucose drink. Further, the display position of the icon 80C of the inspection candidate corresponding to "drink & blood glucose level + HbA1c + other multiple items" on the scale 79 is "after 3 days", and the display position on the scale 87 is 4300 yen. The cost is the sum of the inspection cost of the blood glucose level + HbA1c + other multiple items and the price of the glucose drink.

[0111] Also, the display positions of icon 80D for test candidates corresponding to "Blood collection container arrival & blood glucose level only" and icon 80E for test candidates corresponding to "Blood collection container arrival & blood glucose level + α" on scale 79 are "Tomorrow", and the display positions on scale 87 are slightly higher than those of icons 80A and 80B. This is because transportation costs (e.g., 300 yen) are included when delivering the blood collection container to the testing device 1 again for the costs of "Drink & blood glucose level only" and "Drink & blood glucose level + α". Also, the display position of icon 80F for test candidates corresponding to "Blood collection container arrival & blood glucose level + HbA1c + other multiple items" on scale 79 is "4 days later", and the display position on scale 87 is slightly higher than that of icon 80C. This is because transportation costs are included when delivering the blood collection container to the testing device 1 again for the costs of "Drink & blood glucose level + HbA1c + other multiple items" and "Drink & blood glucose level + α".

[0112] The user can, through the presentation screen 86, quickly recognize the required date and time and cost for the presented test candidates at a glance. Thereby, it is possible to easily compare the test candidates considering both the required date and time and the cost.

[0113] On the presentation screen 86, the user can select the icon of the test candidate and select the decision button 81 to determine the test method desired by the user. Also, by further selecting the item selection button 82, it is possible to additionally specify the item that serves as an indicator when selecting the test candidate. Thereby, it is possible to further add items and compare the test candidates until the user is satisfied.

[0114] When steps ST11 and ST18 are affirmed, the presentation unit 54 displays guidance on the inspection method selected by the user on the touch panel 14 (step ST19). For example, if the user selects "Drink & Blood Glucose Only" on the presentation screen 62 or the like, since blood sampling is required after 60 minutes, the presentation unit 54 displays a guidance screen for making an inspection reservation. FIG. 25 is a diagram showing a guidance screen for inspection reservation. On the reservation guidance screen 89 shown in FIG. 25, the user inputs the time for which they wish to make a reservation into the input box 90. Then, when the reservation button 91 is selected, the reservation is completed. The inspection apparatus 1 is controlled so as not to acquire and inspect the monitoring results of the blood glucose equivalent values of other users from several minutes before the time when the user makes a reservation.

[0115] Subsequent to step ST19, the determination unit 53 stores the acquired monitoring results of the user's blood glucose equivalent values in the storage 13 in association with the acquisition date and time and the abnormal tendency (step ST20). Further, the acquired monitoring results of the user's blood glucose equivalent values are processed in association with the acquisition date and time, the abnormal tendency, and the selected inspection candidate, and so that the user is not identified, and then transmitted to the inspection server 6 (step ST21), and the process ends. When an image of a meal is acquired, the image is also transmitted to the inspection server 6 together. In the inspection server 6, the acquired information is stored.

[0116] The user goes to the installation location of the inspection apparatus 1 at the reserved time, has blood sampled by the analysis apparatus 18, or loads a blood collection container containing the blood sampled using a test kit into the analysis apparatus 18. Thereby, the analysis apparatus 18 analyzes the blood according to the inspection method selected by the user and derives an analysis result. The analysis result is displayed on the touch panel 14. FIG. 26 is a diagram showing a display screen of the analysis result. As shown in FIG. 26, on the analysis result display screen 92, for example, "150 mg / dL", which is the analysis result of the blood glucose value, is displayed.

[0117] As described above, in this embodiment, when the monitoring result of the user's blood glucose equivalent value shows an abnormal trend, test candidates for obtaining biological information related to the blood glucose equivalent value are presented to the user, and guidance corresponding to the test candidates selected by the user is presented to the user. Therefore, the user can perform tests according to the monitoring results of the blood glucose equivalent value using the test device according to this embodiment. In addition, the user will no longer perform tests that do not match the abnormal trend of their own blood glucose level. Therefore, personalized medicine that caters to the user can be promoted.

[0118] In addition, by presenting test candidates that can acquire biological information related to the blood glucose equivalent value with higher accuracy than the measuring instruments 3 and 4, the user can select a test that can accurately grasp the status of their own blood glucose. Therefore, by undergoing the selected test, the user can more accurately grasp the status of their own blood glucose.

[0119] In addition, by accepting the designation of at least one item that serves as an index when the user selects test candidates and presenting the test candidates in a display form corresponding to the designated item, the test candidates can be presented in a display form that reflects the matters that the user wants to emphasize when selecting the test candidates. Therefore, the user can easily select test candidates.

[0120] In addition, by presenting a question to the user for determining the display position of the test candidates on a scale according to the designated item, determining the display position of the test candidates on the scale according to the answer to the question, and presenting the test candidates to the user in a display form that displays an icon representing the test candidates at the determined display position on the scale, the test candidates can be presented to the user in a display form that reflects the item that serves as an index when selecting the test candidates. Therefore, the user can select test candidates in consideration of the items they value.

[0121] In addition, by accepting an additional specification of at least one item that serves as an indicator when selecting a test candidate, and updating the display form of the icon representing the test candidate according to the additionally specified item and presenting the test candidate to the user, the test candidate can be presented in a display form that takes into account a plurality of items that serve as indicators when selecting the test candidate. Therefore, the user can easily select a test candidate.

[0122] In addition, by presenting the user with statistical information on test candidates selected in the past, the user can more easily select a test method suitable for themselves.

[0123] In addition, by accumulating blood glucose equivalent values, abnormal trends, selected test candidates, images of meals, etc. in the test server 6, it becomes possible to use the accumulated information as big data. The accumulated big data can be used for the learning of AI that provides information related to blood glucose levels or as statistical information.

[0124] Note that in the above first embodiment, a test method that cannot be implemented in the test device 1 may be presented as a test candidate. For example, a test in which the user periodically performs self-blood sampling or a test method in which blood is sampled at a hospital may be presented as a test candidate. When such a test method is presented as a test candidate, for example, if the user wants to regularly check their blood glucose level in the future and selects the test method of self-blood sampling blood glucose measurement at home, the presentation unit 54 guides the user to a website that sells a blood glucose meter (SMBG: Self Monitoring of Blood Glucose). FIG. 27 is a diagram showing a guidance screen of a website that sells a blood glucose meter. As shown in FIG. 27, a plurality of websites where a blood glucose meter can be purchased are displayed on the guidance screen 93. The user can purchase a blood glucose meter by accessing the displayed website.

[0125] On the one hand, when an examination method to be performed at a hospital is presented as an examination candidate, if the user wishes to firmly grasp the current status of their blood glucose level and selects a glucose tolerance test at the hospital, the presentation unit 54 guides the user to a hospital near the user's home or workplace where the glucose tolerance test can be performed. FIG. 28 is a diagram showing a guidance screen for guiding the user to a hospital where the glucose tolerance test can be performed. As shown in FIG. 28, hospitals near the user's workplace where the glucose tolerance test can be performed are displayed on the guidance screen 94. Also, the presented hospital names are selectable, and when a hospital name is selected, a list 95 of available reservation dates and times for the glucose tolerance test is displayed. In FIG. 28, Hospital A is selected and a list of available reservation dates and times for Hospital A is shown. The user can select a date and time marked with "○" and select the reservation button 96 to make a reservation for the glucose tolerance test at the selected hospital.

[0126] In the above first embodiment, guidance is provided and the process ends when the user selects an examination from the examination candidates. However, examination candidates that are further stepped up may be proposed for the examination selected by the user. For example, as shown in FIG. 12, when six examination candidates are presented in the case of a large postprandial blood glucose spike, after the user selects any one of the examination candidates, as the next examination candidate, guidance to an examination at a hospital may be provided. FIG. 29 is a diagram showing a guidance screen for the next examination. As shown in FIG. 29, on the guidance screen 97, as the next step of the examination, two examination methods, namely, the GA test and the 1,5AG test at the hospital, and the glucose tolerance test at the hospital are presented. The user can recognize from the guidance screen 97 that it is preferable to perform the GA test and the 1,5AG test at the hospital, or the glucose tolerance test at the hospital next.

[0127] Note that the GA test is a test for glycated albumin, and the 1,5AG test is a test for 1,5-anhydro-D-glucitol. Glycated albumin is a substance formed by the binding of albumin, a type of protein in serum, and glucose, and it is biological information that can indicate the blood glucose level situation 1 to 2 weeks ago. 1,5AG is a sugar in the blood and is the second most abundant sugar after glucose. By measuring 1,5AG as biological information, the blood glucose level situation in the past few days can be known. The glucose tolerance test is a test for measuring blood glucose levels by collecting blood three times after glucose loading.

[0128] Also, in the above first embodiment, for example, when the measured value of the blood glucose equivalent value is insufficient, it may not be possible to determine whether the blood glucose level has an abnormal tendency. For example, the wearing time of the measuring device 3 by the user may be short, and the blood glucose equivalent value may not be monitored enough to determine the postprandial hyperglycemia spike. In such a case, the determination unit 52 cannot determine whether there is an abnormal tendency. Therefore, when the determination unit 52 cannot determine whether there is an abnormal tendency, it is preferable to issue a notification prompting the user to increase the wearing time of the measuring device 3. FIG. 30 is a diagram showing the notification screen. As shown in FIG. 30, a notification 99 saying "Please increase the wearing time of the measuring device." is displayed on the notification screen 98. The user can take an action to increase the wearing time of the measuring device 3 based on the notification screen 98, and thereby it becomes possible to determine whether the subsequent blood glucose equivalent value has an abnormal tendency.

[0129] Also, in the above-described first embodiment, the user may use the camera 28 of the mobile terminal 2 to photograph the meal content and transmit an image of the meal content to the inspection device 1 together with the monitoring result of the blood glucose equivalent value. In this case, in the inspection device 1, within two hours after a meal, the meal content may be discriminated based on the image of the meal content, and inspection candidates may be determined according to the meal content. For example, when the abnormal tendency determined by the determination unit 52 is a small postprandial hyperglycemic spike, if the result of discriminating the meal content shows a meal content with little sugar, it is considered that the postprandial hyperglycemic spike is small due to the influence of the meal. Therefore, the abnormal tendency of the blood glucose equivalent value may be changed to a large postprandial hyperglycemic spike, and the inspection methods (1) to (3) may be determined as inspection candidates.

[0130] Also, in the above-described first embodiment, on the item list screen 70, each time one item serving as an index for selecting inspection candidates is selected, the inspection candidates are presented to the user in a display form using a scale, but it is not limited to this. On the item list screen 70, a plurality of items may be selectable at once. In this case, the display positions of the inspection candidates on the scales of the selected plurality of items are determined, and the inspection candidates are presented to the user in a display form in which the icons of the inspection candidates are displayed at the determined display positions.

[0131] Also, in the above-described first embodiment, when the item selection button 65 is selected, the item list screen 70 is displayed to allow the user to select an item serving as an index for selecting inspection candidates, but it is not limited to this. Before determining the abnormal tendency based on the monitoring result of the blood glucose equivalent value by the inspection device according to the present embodiment, the user may be allowed to select in advance an item serving as an index for selecting inspection candidates. Alternatively, the item serving as an index for selecting inspection candidates from the measuring device 3 may be transmitted to the inspection device 1. In this case, on the inspection candidate presentation screen 62, a button replacing the item selection button 65 is displayed, and by selecting that button, the inspection candidates are presented to the user in the display form shown in FIGS. 21, 22, or 24.

[0132] In addition, when allowing the user to select in advance the items serving as indicators for selecting test candidates, the user may select items including risk checks for various diseases. In such a case, the determination unit 53 may determine a test method including other multi-item tests as a test candidate. For example, the test methods (2) and (3) shown in FIG. 8 may be determined as test candidates.

[0133] Also, in the above-described first embodiment, when an item serving as an indicator for selecting a test candidate is selected on the item list screen 70, a question is asked to the user, and the display position of the test candidate on the scale is determined according to the answer to the question. However, the present invention is not limited to this. Without asking a question, the display position of the test candidate on the scale may be determined according to the degree of preference of the selected item. For example, when the user selects the accuracy of the test, on the scale representing the accuracy of the test, the display position is determined such that the icons of the test candidates with higher test accuracy are displayed at higher accuracy positions.

[0134] Also, in the above-described first embodiment, when the blood glucose equivalent value does not show an abnormal trend, as shown in FIG. 11, a notification of "The blood glucose level does not show an abnormal trend. Please continue with your current lifestyle." is made. However, the content of the notification is not limited to this. When the blood glucose equivalent value does not show an abnormal trend but shows an upward trend, it is preferable to make a notification including advice to pay attention to the lifestyle.

[0135] Also, in the above first embodiment, although the blood glucose equivalent value is measured by the measuring instruments 3 and 4, it is not limited thereto. Instead of measuring the blood glucose equivalent value by the measuring instruments 3 and 4, a urine sugar test may be performed to measure urine sugar. In this case, the measured urine sugar value becomes an example of the first biological information. In the case of a urine sugar test, since the urine sugar value can be obtained by using a urine sugar test device, it may be used as the blood glucose equivalent value. The urine sugar test device is an example of a measuring instrument. In this case, the urine sugar test device may be provided with a communication function with the portable terminal 2, and the measured urine sugar value may be transmitted to the portable terminal 2 so that the portable terminal 2 monitors the blood glucose equivalent value based on the urine sugar value.

[0136] On the other hand, when performing a urine sugar test using a test strip, the color of the test strip changes according to the urine sugar. In this case, an image of the test strip is acquired by photographing the test strip with the camera 28 of the portable terminal 2, the urine sugar value is accumulated by recognizing the color of the test strip from the image of the test strip in the portable terminal 2, and the accumulated urine sugar value is transmitted from the portable terminal 2 to the inspection device 1 as a monitoring result of the blood glucose equivalent value. In this case, since the measuring instrument is not required, the user does not need to prepare the measuring instruments 3 and 4 or the urine sugar test device. Also in this case, the abnormal tendency of the blood glucose equivalent value may be determined from the urine sugar value acquired in the portable terminal 2.

[0137] Also, instead of the blood glucose equivalent value measured by the measuring instruments 3 and 4, the blood glucose equivalent value may be monitored by using an AGP (Ambulatory glucose profile). AGP is an analytical method useful for reading the tendency of blood glucose fluctuations, that is, the blood glucose trend, from the blood glucose values or glucose values in interstitial fluid for several days obtained by continuous measurement (https: / / dm-net.co.jp / trend / agp / 001.php). By using AGP, it becomes easy to grasp the time zones with a high possibility of hypoglycemia and hyperglycemia during a day, as well as the time zones with large fluctuations in blood glucose values. Therefore, by monitoring the blood glucose equivalent value by using AGP, it is possible to easily determine the abnormal tendency of the blood glucose equivalent value.

[0138] Also, in the above first embodiment, the blood glucose equivalent value measured by the measuring instruments 3 and 4 may be monitored, and the comparison result between the monitoring result of the blood glucose equivalent value and the test result obtained by the user through blood sampling may be presented to the user. FIG. 31 is a diagram showing the comparison result between the monitoring result of the blood glucose equivalent value and the test result obtained by the user through blood sampling. In FIG. 31, the solid line indicates the monitoring result of the blood glucose equivalent value, and the broken line indicates the test result obtained through blood sampling. As shown in FIG. 31, the blood glucose equivalent value measured by the measuring instruments 3 and 4 tends to be higher than the actual blood glucose. As shown in FIG. 31, by presenting the comparison result between the monitoring result of the blood glucose equivalent value and the test result obtained by the user through blood sampling to the user, the user can judge the deviation between the current blood glucose equivalent value and the actual blood glucose value.

[0139] Also, in the above first embodiment, when the test method (3) is selected, the blood collected by the user will be delivered to the testing center. Also, when the test methods (1), (2), or (4) are selected, or when the user wishes to have the blood collected delivered to the testing center for testing, in this case, the presenting unit 54 of the testing device 1 will display a guidance screen for performing the delivery procedure on the touch panel 14. FIG. 32 is a diagram showing the guidance screen for performing the delivery procedure of the test result. As shown in FIG. 32, boxes for entering the user's name, address, phone number, and email address are displayed on the guidance screen 100. The user enters the necessary information and selects the determination button 101. Thereby, the destination of the specimen is mailed to the user's email address. The user delivers the specimen to the mailed destination by themselves. Also, the test result will be delivered to the user at a later date. On the other hand, the test result can also be confirmed on the testing device 1. In this case, the test result is transmitted from the testing center to the testing device 1, and the user can display the test result on the testing device 1 by entering their own ID, etc. on the testing device 1.

[0140] Note that the user has registered with the inspection device 1 for use. When the user notifies the inspection center of user information such as name, address, and phone number for user registration, the inspection device 1 may access the inspection server 6 to obtain the user information, and based on the obtained user information, display a guidance for confirming the user's name, address, phone number, etc. on the touch panel 14.

[0141] Also, when delivering the specimen, a storage box for accommodating the specimen may be provided in the inspection device 1, the specimen may be accommodated in the storage box, and the specimen may be collected from the storage box at a determined time and delivered to the inspection center.

[0142] In addition, in the above first embodiment, a postprandial hyperglycemia spike is determined as an abnormal tendency of the blood glucose equivalent value, but it is not limited thereto. As abnormal tendencies determined by monitoring the blood glucose equivalent value, fasting hyperglycemia, hypoglycemia, or nocturnal hyperglycemia may be determined. For example, in the case of hypoglycemia, the candidate tests to be presented include a 5-hour load test, a salivary cortisol test, a salivary cortisol + DHEA test, a delayed food allergy test, and an organic aciduria measurement. The 5-hour load test is an almost essential test for hypoglycemia. The salivary cortisol test is a test for determining whether a person is in a fatigued state due to stress. The DHEA test is a test for dehydroepiandrosterone sulfate. Dehydroepiandrosterone sulfate is a type of male hormone. The delayed food allergy test is a test for determining the severity of intestinal disorders. The organic aciduria measurement is a test for determining whether fungi are growing in the intestinal tract and producing toxins.

[0143] [Second Embodiment] In the above-described first embodiment, the form of presenting guidance to the user according to the test candidates for acquiring biological information related to the blood glucose equivalent value according to the abnormal tendency of the blood glucose equivalent value has been described. However, the present disclosure is not limited to this. For example, the technology of the present disclosure may be applied to a form of presenting guidance to the user according to the test candidates for acquiring biological information required when diagnosing various diseases such as infectious diseases and cancer. Among various diseases, it is known that some diseases show abnormal tendencies in physiological information such as heartbeat, blood pressure, respiration, electrocardiogram, maximum oxygen uptake, arterial blood oxygen saturation, and body temperature when affected. In particular, if the abnormal tendency of various physiological information can be determined by the technology of this embodiment before the user becomes aware of the symptoms of the disease, and the user can be recommended to undergo various tests when there is an abnormal tendency, it can contribute to the early detection of the disease.

[0144] Hereinafter, as a specific example of such a disease, an example applying coronavirus disease 2019 (COVID-19) will be described. In this embodiment, instead of the blood glucose equivalent value of the first embodiment, the heartbeat is applied as the first biological information. It is assumed that the heartbeat is acquired by a sensor provided in the measuring device 3. Further, instead of glucose, urine sugar, blood glucose level, HbA1c, glycated albumin, and 1,5AG of the first embodiment, the test results regarding the presence or absence of infection with the novel coronavirus are applied as the second biological information. In this embodiment, for the same configurations and operations as those in the first embodiment, some overlapping descriptions will be omitted.

[0145] Figure 33 is a schematic diagram showing an example of the changes in the heart rate variability (HRV), the amount of virus in the body, the amount of antibodies in the body, and the amount of virus excretion in patients with coronavirus disease. In Figure 33, the heart rate variability is shown as a thick solid line, the amount of virus in the body as a thin solid line, the amount of antibodies in the body as a dashed-dotted line, and the amount of virus excretion as a dashed line. The horizontal axis of Figure 33 represents the days after onset as positive and the days before onset as negative, with the onset day of symptoms such as fever and cough being set as day 0. Heart rate variability is a value representing the variation in the time interval (RRI: R-R Interval) between each heartbeat. Specifically, heart rate variability is represented by the standard deviation of RRI (SDNN: Standard Deviation of the R-R interval) and / or the square root of the mean value of the squares of the differences between two consecutive RRIs (rMSSD: root Mean Square of Successive R-R interval Differences) within a predetermined period, etc.

[0146] As shown in Figure 33, in the case of coronavirus disease, an abnormal tendency is seen where the amount of virus in the body begins to increase rapidly about 5 days before the onset day, and accordingly, the heart rate variability decreases. This is because in non-infected individuals, the heart rate increases during exercise and in a tense state, etc., and decreases during relaxation, while in infected individuals, the heart's followability is poor and the degree of increase or decrease in the heart rate becomes smaller. Subsequently, around the onset day, the amount of virus in the body reaches its maximum value, the heart rate variability reaches its minimum value, and about 10 days after the onset day, the amount of antibodies in the body increases and the amount of virus in the body begins to decrease, and the heart rate variability gradually returns to normal.

[0147] In tests related to coronavirus disease, nasal swabs, saliva, and blood are used as specimens that can be self - collected by users (details will be described later). Therefore, the analysis device 18 in the present embodiment derives test results regarding the presence or absence of coronavirus infection as the second biological information by analyzing the user's nasal swabs, saliva, and blood. For this purpose, the analysis device 18 has a mechanism for collecting the user's nasal swabs, saliva, and blood and a mechanism for obtaining nasal swabs, saliva, and blood from the test kit 20A described later, etc.

[0148] The storage case 20 in the present embodiment houses a plurality of test kits 20A for collecting the user's nasal swabs, saliva, and blood respectively. The test kit 20A includes, for example, a cotton swab for collecting nasal swabs, a container for collecting saliva, and a blood sampling instrument.

[0149] The acquisition unit 51 acquires the heart - rate monitoring result transmitted from the communication I / F35 of the measuring device 3 by receiving it through the communication I / F15. In the present embodiment, for example, the heart - rate monitoring result measured in the most recent 24 hours is acquired.

[0150] The determination unit 52 determines whether the heart rate has an abnormal tendency based on the heart - rate monitoring result acquired by the acquisition unit 51. Specifically, the determination unit 52 calculates the heart - rate variation from the heart - rate monitoring result transmitted from the measuring device 3, and determines that the heart rate has an abnormal tendency when there is a situation where the heart - rate variation is equal to or less than a predetermined threshold Th11. In addition, the determination unit 52 determines that the degree of the abnormal tendency of the heart rate is large when the heart - rate variation is equal to or less than a threshold Th12 (where Th12 < Th11), and determines that the degree of the abnormal tendency of the heart rate is small when the heart - rate variation is less than Th11 and exceeds Th12.

[0151] In addition, the determination unit 52 may determine the abnormal tendency of the heartbeat by using representative values such as the average value and the median value of the heartbeat fluctuations per unit time within a predetermined period (for example, the most recent 24 hours). This is because it is preferable not to regard a temporary increase in the heartbeat fluctuations during exercise and in a tense state as an abnormal tendency.

[0152] In addition, when there is a situation where the heartbeat fluctuation is increasing (becoming equal to or greater than the threshold value Th11), the determination unit 52 determines whether the increase is temporary due to exercise and a tense state or the like. When it is determined to be a temporary increase, the increase period may be excluded, and it may be determined whether the heartbeat has an abnormal tendency. The determination as to whether the heartbeat fluctuation is a temporary increase may be made by comparing it with the temporary increase tendency of the heartbeat fluctuation in the same previous situation. Specifically, for example, a temporary increase pattern of the heartbeat fluctuation is stored in the storage 13 in advance, and the determination unit 52 may determine whether the heartbeat fluctuation is a temporary increase by comparing the stored increase pattern with the monitoring result of the heartbeat.

[0153] When the determination unit 52 determines that the heartbeat has an abnormal tendency, the decision unit 53 determines the examination candidates to be recommended to the user.

[0154] With reference to FIG. 34, a specific example of the method for determining examination candidates by the decision unit 53 will be described. FIG. 34 is a table showing examination methods related to coronavirus disease. In FIG. 34, for six types of examination methods (C1) to (C6), the specimen type, the biological information obtained, the cost, and the required time are shown as examination information. The table shown in FIG. 34 is stored in the storage 13 as a table, for example. Note that the content of FIG. 34 is an example, and the examination information, the evaluation of each item, and the conditions may be updated as appropriate according to the epidemic situation, the treatment situation, and the progress of the examination method of coronavirus disease.

[0155] The inspection methods (C1) to (C2) are each a PCR (Polymerase Chain Reaction) test using the nasal wash fluid and saliva of the subject as samples. The inspection methods (C3) to (C4) are each an antigen quantification test using the nasal wash fluid and saliva of the subject as samples. The inspection method (C5) is an antigen qualitative test using the nasal wash fluid of the subject as a sample. The inspection methods (C1) to (C5) can obtain, as the second biological information, the test results on whether the subject is currently infected with the novel coronavirus. The inspection method (C6) is an antibody test using blood as the sample, and can obtain, as the second biological information, the test results on whether the subject has been infected with the novel coronavirus in the past. The determination unit 53 selectively determines the inspection candidates from among the plurality of inspection methods (C1) to (C6) that include such designation of the type of sample and that are for obtaining the second biological information from the sample.

[0156] In addition, FIG. 34 shows various items that serve as indicators when the user selects the presented inspection candidates. Since the definitions and evaluation methods of the various items are the same as those in the first embodiment described above, the description thereof is omitted. However, with regard to accuracy, the higher the degree (so-called sensitivity) of being able to detect a positive person as positive, the greater the degree of preference.

[0157] In addition, FIG. 34 shows various conditions when the determination unit 53 determines inspection candidates. Specifically, the inspectable period, as well as conditions regarding the suitability of inspection for those with a low abnormal tendency, asymptomatic individuals, and high-risk individuals, are shown. The "inspectable period" indicates a period during which, when testing a positive person, the degree of detectability as positive (so-called sensitivity) is relatively high and the test result can be trusted. A "person with a low abnormal tendency" is a person determined by the determination unit 52 to have a low degree of abnormal tendency. An "asymptomatic person" means a person who has not developed symptoms such as fever and cough. For those with a low abnormal tendency and asymptomatic individuals, it is considered that a highly sensitive test method should be adopted to prevent overlooking due to false negatives, so a test method with relatively low sensitivity is not acceptable. A "high-risk person" is a person having risk factors such as severe illness and high treatment difficulty, for example, the elderly, those with underlying diseases, and pregnant women, etc. For high-risk individuals, it is considered that the test should be performed more accurately in order to perform appropriate treatment promptly, so a test method with relatively low sensitivity is not acceptable.

[0158] The determination unit 53 refers to the table in FIG. 34 and determines, as inspection candidates, inspection methods suitable for various conditions among the inspection methods (C1) to (C6). As shown in FIG. 34, in the case of coronavirus disease, the inspectable period is determined based on the onset date. Therefore, first, the determination unit 53 estimates the onset date based on the heartbeat fluctuation, and determines the inspection candidates according to whether the current time is included in the inspectable period based on the estimated onset date. For example, if it is estimated that the current time is two days before the onset date, the determination unit 53 determines the inspection methods (C1) to (C3) as inspection candidates. Also, for example, if it is estimated that the current time is four days after the onset date, the determination unit 53 determines the inspection methods (C1) to (C5) as inspection candidates. Also, for example, if it is estimated that the current time is 15 days or more after the onset date, the determination unit 53 determines the inspection method (C6) as an inspection candidate.

[0159] As a method for estimating the onset date, for example, based on the fact that there is a time lag of about 5 days from when the heartbeat fluctuation begins to show an abnormal tendency until the onset (see Fig. 33), the onset date may be estimated to be about 5 days after the time when the determination unit 52 determines that the heartbeat is showing an abnormal tendency. Also, for example, a learning model that has learned, as learning data, pairs of the transition data of the heartbeat fluctuations of patients infected with the novel coronavirus, and the actual onset date, and that takes the transition data of the heartbeat fluctuations as input and outputs the estimated onset date may be used.

[0160] Second, the determination unit 53 determines the test candidates according to the degree of the abnormal tendency of the heartbeat determined by the determination unit 52. For example, when the determination unit 52 determines that the abnormal tendency is small, the determination unit 53 determines the test methods (C2), (C4), and (C6) as the test candidates. Also, the determination unit 53 determines the test candidates in the same way even when the user is an asymptomatic person. On the other hand, when the determination unit 52 determines that the abnormal tendency is large, the determination unit 53 determines the test methods (C1) to (C6) as the test candidates.

[0161] Third, the determination unit 53 determines the test candidates according to the risk factors the user has. For example, when the user is a high-risk person, the determination unit 53 determines the test methods (C1) to (C4) and (C6) as the test candidates. On the other hand, when the user is not a high-risk person, the determination unit 53 determines the test methods (C1) to (C6) as the test candidates.

[0162] According to the above first to third determinations, the determination unit 53 determines the final test candidates. For example, if the current time is 4 days after the onset date, the determination unit 52 determines that the abnormal tendency is large, and the user is a symptomatic person and not a high-risk person, the determination unit 53 determines the test methods (C1) to (C5) as the test candidates. Also, for example, if the current time is 4 days after the onset date, the determination unit 52 determines that the abnormal tendency is large, and the user is an asymptomatic person and a high-risk person, the determination unit 53 determines the test methods (C2) and (C4) as the test candidates.

[0163] The prompting unit 54 prompts the user with the inspection candidates determined by the determination unit 53. FIGS. 35 and 36 are diagrams showing an example of a prompting screen that prompts the user with inspection candidates in a display form in which icons of the inspection candidates are displayed on a scale when two items, "cost" and "accuracy", are selected by the user. On the prompting screens 86X in FIGS. 35 and 36, a scale 88 representing accuracy is displayed orthogonally to a scale 87 representing cost, and the icons 801 to 805 of the inspection candidates are arranged and displayed two-dimensionally according to the cost and accuracy. The icons 801 to 805 respectively correspond to the inspection methods (C1) to (C5).

[0164] FIG. 35 shows a prompting screen when the current time is 4 days after the onset date, the determination unit 52 determines that the abnormal tendency is large, and the user is a symptomatic person and not a high-risk person. FIG. 36 shows a prompting screen when the current time is 4 days after the onset date, the determination unit 52 determines that the abnormal tendency is large, and the user is an asymptomatic person and a high-risk person. With the prompting screen 86X, the user can recognize at a glance the cost and accuracy of the presented inspection candidates. Thereby, it is possible to easily compare the inspection candidates considering both the cost and the accuracy.

[0165] The prompting unit 54 accepts the user's selection of the presented inspection candidates. Then, using the touch panel 14, the prompting unit 54 prompts the user with guidance corresponding to the selected inspection candidate. For example, the user is guided to take out the inspection kit 20A for self-collecting any one of nasal washings, saliva, and blood from the storage case 20 according to the selected inspection candidate. In addition, the prompting unit 54 prompts the user with guidance on the method of self-collection. The information regarding these guides may be stored in the storage 13. The prompting unit 54 may read out the guidance corresponding to the inspection candidate selected by the user from the storage 13 and display the read-out guidance on the touch panel 14. The user self-collects any one of nasal washings, saliva, and blood according to the guidance.

[0166] In addition, the presentation unit 54 may present, as guidance, support information that supports the implementation of the selected test candidate's test and that is transmitted in real time from a remote location. Further, the inspection device 1 may be provided with a camera that photographs the user, and the presentation unit 54 may transmit a moving image obtained by photographing with the camera the state in which the user is performing the inspection of the selected test candidate to a remote location. Specifically, by connecting the computer owned by the medical staff and the inspection device 1 via a network, the medical staff at a remote location may be able to guide the user in the method of self-sampling in real time. In this case, the camera provided in the inspection device 1 may photograph the state in which the user self-samples nasal mucus, saliva, and blood and transmit it to the computer of the medical staff at a remote location. Further, the inspection device 1 may be provided with a speaker and reproduce voice guidance from the medical staff.

[0167] In addition, when the determination unit 53 determines that none of the inspection methods are suitable, for example, when the current time is three days or more before the onset date, the presentation unit 54 may present guidance to that effect. For example, guidance such as "An abnormal tendency is observed in the heartbeat, but accurate results cannot be obtained even if an inspection is performed at this time. Let's continue to monitor the heartbeat." Further, when the determination unit 52 determines that the heartbeat does not show an abnormal tendency, the presentation unit 54 may present guidance to that effect. For example, guidance such as "Currently, the heartbeat does not show an abnormal tendency. Let's continue to take infection prevention measures."

[0168] As described above, in this embodiment, when the monitoring result of the user's heartbeat shows an abnormal tendency, a test candidate for obtaining a test result regarding the presence or absence of infection with the novel coronavirus related to the heartbeat is presented to the user, and guidance corresponding to the test candidate selected by the user is presented to the user. For this reason, the user can perform a test according to the monitoring result of the heartbeat using the test device according to this embodiment. In particular, in the case of the novel coronavirus infection, the amount of virus discharged from an infected person, that is, the infectivity to others, peaks near the onset date (see Fig. 33). Therefore, by determining an abnormal tendency of the heartbeat before the onset date and presenting the user with a suggestion to receive a test, it is possible to contribute to preventing the spread of the infection.

[0169] In addition, in the above-described second embodiment, the form in which the determination unit 52 determines an abnormal tendency of the heartbeat based on the heartbeat fluctuation has been described, but the present invention is not limited to this. Instead of the heartbeat fluctuation, the determination unit 52 may determine that the heartbeat has an abnormal tendency when the value of the heart rate is equal to or higher than a predetermined threshold for a predetermined period (for example, three days). According to such a form, it is possible to contribute to the early detection of a disease in which the heart rate remains high at the time of illness. Further, instead of the heartbeat fluctuation, the determination unit 52 may determine that the heartbeat has an abnormal tendency when the temporal fluctuation of the heart rate (the difference between the maximum value and the minimum value of the heart rate over a predetermined period (for example, three days)) is equal to or higher than a predetermined threshold. According to such a form, it is possible to contribute to the early detection of a disease in which the heart rate rises rapidly at the time of illness.

[0170] In the above-described second embodiment, the form in which the heartbeat is applied as the first biological information has been described, but the present invention is not limited to this. In the second embodiment, at least one of physiological information such as heartbeat, blood pressure, respiration, electrocardiogram, maximum oxygen uptake, arterial blood oxygen saturation, and body temperature may be applied as the first biological information. These physiological information are acquired, for example, by sensors provided in wearable terminals such as smartwatches.

[0171] In addition, in the above-described second embodiment, a form in which the test result regarding the presence or absence of infection with the novel coronavirus is applied as the second biological information has been described, but the present invention is not limited thereto. In the second embodiment, the diagnosis result of the user's disease may be applied as the second biological information related to the physiological information. As the "diagnosis result of the disease", for example, the analysis result of components using body fluids such as the user's blood, urine, feces, nasopharyngeal swab, nasal swab, and saliva as specimens, and the detection result of pathogens such as viruses and bacteria can be applied. Also, for example, the reading result of an image taken by a method such as computed tomography (CT), magnetic resonance imaging (MRI), or ultrasonic wave using organs such as the user's stomach, large intestine, lung, uterus, and breast as specimens can be applied.

[0172] In addition, in the above-described second embodiment, the diagnosis results of a plurality of different types of diseases may be applied as the second biological information related to the physiological information. For example, a test related to novel coronavirus infection and a test related to influenza virus infection may both be presented as test candidates. Also, a guidance to the effect that such tests related to a plurality of different types of diseases are to be received simultaneously may be presented. In these cases, since the diagnosis of various diseases can be recommended, it can contribute to the early detection of diseases.

[0173] In the second embodiment described above, the onset date and information on whether the user is an asymptomatic person or a high-risk person may be input by the user via, for example, the touch panel 14. FIG. 37 is a diagram showing a question presentation screen for inputting these. As shown in FIG. 37, four questions Q1 to Q4 are displayed on the question presentation screen 75X. The user answers questions Q1 to Q4 with YES or NO. When the answer to question Q1 is YES, the determination unit 53 identifies the onset date by having the onset date input into the input box 76X. When the answer to question Q1 is NO, the determination unit 53 identifies that the user is an asymptomatic person. When at least one of questions Q2 to Q4 is YES, the determination unit 53 identifies that the user is a high-risk person. When the user selects the answer completion button 77 after answering, the determination unit 53 determines the test candidate according to the answer results of the four questions Q1 to Q4.

[0174] Also, in the second embodiment described above, the determination unit 53 may estimate whether the user is an asymptomatic person based on the fact that there is a time lag of about five days from when the heartbeat shows an abnormal tendency until the onset (see FIG. 33). For example, if the current time is the second day after the heartbeat shows an abnormal tendency, the determination unit 53 may estimate that the user is an asymptomatic person who has not yet had an onset. Also, for example, by measuring the body temperature with the measuring device 3, the determination unit 53 determines the presence or absence of fever, and if there is no fever, it may be estimated that the user is an asymptomatic person.

[0175] In addition, in the above-described second embodiment, while the form in which the determination unit 53 estimates the onset date has been described in accordance with the fact that the testable period for COVID-19 is determined based on the onset date, it is not limited thereto. For example, when influenza virus infection is the subject of testing, the period from infection to onset is as short as about 1 to 2 days, and since the difference between the day when an abnormal tendency begins to be observed in the first biological information and the onset date is small, there is little significance in estimating the onset date. Also, for example, when various lifestyle-related diseases are the subject of testing, it is difficult to accurately estimate the onset date. However, even in these diseases, the appropriate test method may differ depending on the elapsed time since the abnormal tendency began to be observed. Therefore, the determination unit 53 may determine the test candidates according to the elapsed time from the point in time when it is determined that the first biological information has an abnormal tendency to the current time.

[0176] In addition, in the above-described second embodiment, whether the user is a close contact may be applied as a condition for determining the test candidates. In the case of a close contact, since the possibility of being positive is relatively high, it is considered that a highly sensitive test method should be adopted to prevent overlooking due to false negatives. Therefore, a test method with relatively low sensitivity may be excluded. Whether the user is a close contact may be detected, for example, by a known COVID-19 contact confirmation application.

[0177] In addition, in the above-described second embodiment, after performing a test for the presence or absence of COVID-19 infection, the test device 1 may determine whether to continue monitoring the heartbeat by feeding back the test result. For example, if the test result is negative despite performing a COVID-19 test because the determination unit 52 has determined that the heartbeat has an abnormal tendency, it may be determined that the heartbeat monitoring should be continued. In particular, when the user falls into any of those with a small abnormal tendency, asymptomatic individuals, high-risk individuals, and close contacts, it is considered that the risk of overlooking due to false negatives and acute changes in the receptor is high, so it is preferable to determine that the heartbeat monitoring should be continued.

[0178] Specifically, the acquisition unit 51 acquires the test result regarding the presence or absence of infection with the novel coronavirus. The test result may be transmitted from the analysis device 18 to the acquisition unit 51, for example, or may be input by the user via the touch panel 14. When the acquired test result is negative, the presentation unit 54 determines that the monitoring of the heartbeat should be continued and presents guidance to that effect to the user. When the monitoring of the heartbeat is continued, the determination unit 52 determines whether the abnormal tendency of the heartbeat has become more prominent and whether the abnormal tendency of the heartbeat continues. When it is determined by the determination unit 52 that the abnormal tendency of the heartbeat has become prominent or continues, the decision unit 53 determines again the test candidates to be recommended to the user.

[0179] Also, in the above-described second embodiment, the test methods (C1) to (C6) in FIG. 34 do not include the PCR test, antigen quantification test, and antigen qualitative test in which the subject is a nasopharyngeal swab fluid, which are generally used as test methods for the novel coronavirus infection. This is because it is difficult to self-collect nasopharyngeal swab fluid. However, for example, by arranging medical staff near the test device 1 so that the medical staff collects the user's nasopharyngeal swab fluid, the PCR test, antigen quantification test, and antigen qualitative test using the nasopharyngeal swab fluid as the subject can also be used as test candidates.

[0180] Also, in the above-described second embodiment, in any of the test methods (C1) to (C6) in FIG. 34, it may be guided to deliver the specimen collected by the test kit 20A to the test center, and the test of the specimen may be performed at the test center. In this case, the presentation unit 54 may transmit the user's heartbeat data and the test candidates determined by the decision unit 53 to the test center. According to such a form, it is possible to assist the medical staff at the test center in determining whether the test method selected by the user is appropriate. In these cases, the test device 1 may not include the analysis device 18.

[0181] In each of the above-described embodiments, the presentation unit 54 presents the inspection candidates to the user by displaying them on the touch panel 14. However, the present invention is not limited to this. The presentation unit 54 may present the inspection candidates to the user by voice.

[0182] In each of the above-described embodiments, the inspection apparatus 1 may be provided with a mechanism for cleaning locations that the user may come into contact with, such as the touch panel 14, the housing of the inspection apparatus 1, and the periphery of the installation location of the inspection apparatus 1, each time the user finishes using the inspection apparatus 1. Examples of the cleaning means include wiping with a cloth or the like, spraying a disinfectant solution, and irradiating with ultraviolet rays. According to such a configuration, even if nasal mucus, saliva, blood, etc. self-collected by the user adhere to these locations, it does not become unhygienic, and the spread of infectious diseases can be prevented.

[0183] In each of the above-described embodiments, the monitoring results of the first biological information measured by the measuring instruments 3 and 4 are transmitted to the inspection apparatus 1. However, the present invention is not limited to this. The first biological information measured by the measuring instruments 3 and 4 may be transmitted to the mobile terminal 2, and the monitoring results of the first biological information may be transmitted from the mobile terminal 2 to the inspection apparatus 1.

[0184] In each of the above-described embodiments, the monitoring results of the first biological information measured by the measuring instruments 3 and 4 are transmitted to the inspection apparatus 1, and the determination unit 52 determines the abnormal tendency of the first biological information based on the monitoring results of the first biological information. However, the present invention is not limited to this. In the measuring instruments 3 and 4, the abnormal tendency of the first biological information may be determined based on the monitoring results of the first biological information, and the determination result may be transmitted to the inspection apparatus 1. In this case, the measurement program 32 will perform the process of determining the abnormal tendency. Further, in the inspection apparatus 1, the determination unit 52 does not perform the determination, and the determination unit 53 determines the inspection candidates based on the received determination result.

[0185] Further, the measuring devices 3 and 4 may transmit the first biological information measured by them to the mobile terminal 2. The mobile terminal 2 may determine an abnormal tendency of the first biological information based on the monitoring result of the first biological information, and transmit the determination result from the mobile terminal 2 to the inspection device 1. In this case, the analysis program 22 will perform the process of determining the abnormal tendency. Also, in the inspection device 1, the determination unit 52 does not need to make a determination, and the determination result received may be used for the decision unit 53 to determine the inspection candidates.

[0186] Also, in each of the above embodiments, for example, as the hardware structure of a processing unit (Processing Unit) that executes various processes such as the acquisition unit 51, the determination unit 52, the decision unit 53, and the presentation unit 54, various processors (Processor) shown below can be used. As described above, among the various processors, in addition to the CPU which is a general-purpose processor that executes software (program) and functions as various processing units, there are also programmable logic devices (Programmable Logic Device: PLD) such as FPGA (Field Programmable Gate Array) which are processors whose circuit configuration can be changed after manufacturing, and dedicated electric circuits and the like which are processors having a circuit configuration designed specifically for executing specific processes such as ASIC (Application Specific Integrated Circuit).

[0187] One processing unit may be composed of one of these various processors, or may be composed of a combination of two or more processors of the same type or different types (for example, a combination of multiple FPGAs or a combination of a CPU and an FPGA). Also, a plurality of processing units may be composed of one processor.

[0188] As an example of configuring a plurality of processing units with a single processor, first, as represented by computers such as clients and servers, one processor is configured by a combination of one or more CPUs and software, and this processor functions as a plurality of processing units. Second, as represented by a System On Chip (SoC), there is a form in which a processor that realizes the functions of the entire system including a plurality of processing units with a single IC (Integrated Circuit) chip is used. Thus, various processing units are configured using one or more of the above various processors as a hardware structure.

[0189] Furthermore, as a hardware structure of these various processors, more specifically, circuitry combining circuit elements such as semiconductor elements can be used.

Explanation of Signs

[0190] 1 Inspection device 2 Mobile terminal 3,4 Measuring instrument 4A Filament 5 Network 6 Inspection server 10 Inspection support system 11,21,31 CPU 12 Inspection program 13,23,33 Storage 14,24,34 Touch panel 15,25,35,43 Communication I / F 16,26,36,42 Memory 17,27,37 Network I / F 18 Analysis device 19,29,39 Bus 20 Housing case 22 Analysis program 28 Camera 32 Measurement program 41 Processor 44 Sensor 51 Acquisition unit 52 Judgment Unit 53 Decision Unit 54 Presentation Unit 60 Notification Screen 61 Notification 62, 62A, 62B, 62C Presentation Screen 63, 63A, 63B, 63C Inspection Candidate 64 Statistical Information Reference Button 65 Item Selection Button 66 Decision Button 67 Explanation 68 Statistical Information 69 Action Plan 70 List Screen 71 Checkbox 72 Item Designation Button 75, 75X, 84 Question Presentation Screen 76, 76X, 90 Input Box 77, 85 Answer Completion Button 78, 78A, 86, 86X Presentation Screen 79, 87, 88 Scale 80A~80I, 801~805 Icons of Inspection Candidates 81 Decision Button 82 Item Selection Button 89, 93, 94, 97 Guidance Screen 91, 96 Reservation Button 92 Analysis Result Display Screen 98 Notification Screen 99 Notification 100 Guidance Screen for Delivery Procedures 101 Decision Button

Claims

1. At least one processor; The processor, Obtaining a determination result as to whether or not the first biological information of the user is showing a tendency toward abnormality, the determination result being determined based on a monitoring result of the first biological information of the user; If the determination result indicates the tendency toward abnormality, presenting to the user at least one candidate test for acquiring second biological information related to the first biological information; Accepting designation of at least one item that serves as an indicator for a user to select the presented test candidates; The examination candidates are presented in a display format according to the designated items. Inspection equipment.

2. The processor, presenting the user with a question for determining a display position of the candidate test on at least one scale according to the at least one specified item; determining a display position of the candidate test on the scale in response to the answer to the question; The candidate examinations are presented to the user in a display format in which an icon representing the candidate examination is displayed at the determined display position on the scale.

2. The inspection device according to claim 1.

3. The processor, After displaying the icon representing the candidate test, a designation of addition of the item by the user can be accepted; When the designation of the item is added, the display form of the icon representing the examination candidate is updated.

3. The inspection device according to claim 2.

4. The processor repeats accepting a designation of an additional item, presenting a question corresponding to the added item, and updating a display mode of the candidate test until a candidate test is selected by the user.

4. The inspection device according to claim 3.

5. The items include at least one of the following: the cost of the test, the sense of security when the specimen is collected, the degree of restraint during the test, whether the test is invasive or non-invasive, the time required to obtain the test results, whether risk checks for various diseases are included, and the accuracy of the test. The inspection device according to any one of claims 1 to 4.

6. The processor selectively determines the candidate test from among a plurality of test methods including a designation of a type of subject and for acquiring the second biological information from the subject. The inspection device according to any one of claims 1 to 5.

7. A candidate test for collecting a sample from the user to obtain the second biological information is presented by the processor, and when the candidate test is selected, the processor presents a guide for collecting the sample to the user; The second biological information based on the sample collected by the user is acquired. The inspection device according to any one of claims 1 to 6.

8. The processor presents the second biometric information to the user.

8. The inspection apparatus according to claim 7.

9. The test candidates include test candidates that can obtain the second biometric information with higher accuracy than the first biometric information. The inspection device according to any one of claims 1 to 8.

10. The processor determines the test candidates according to the degree of the abnormal tendency. The inspection device according to any one of claims 1 to 9.

11. The processor determines the test candidate according to an elapsed time from a time when the first biological information was determined to have the tendency toward abnormality to a current time. The inspection device according to any one of claims 1 to 10.

12. The processor determines the test candidates according to risk factors possessed by the user. The inspection device according to any one of claims 1 to 11.

13. The processor presents statistical information of previously selected test candidates to the user.

13. An inspection device according to any one of claims 1 to 12.

14. the first biological information is a blood glucose equivalent value having a correlation with a blood glucose level, The second biological information includes at least one of a blood glucose level and HbA1c.

14. An inspection device according to any one of claims 1 to 13.

15. The abnormal tendency is a postprandial hyperglycemic spike.

15. An inspection device according to any one of claims 1 to 14.

16. The processor determines the test candidates based on the diet of the user.

16. The inspection apparatus according to claim 15.

17. The processor determines the test candidates based on the mealtime of the user.

17. The inspection device according to claim 15 or 16.

18. The processor presents a test candidate including an action of drinking a glucose drink when a time elapsed since a meal based on the meal time has passed a predetermined time.

18. The inspection apparatus according to claim 17.

19. the first biological information is at least one of a heart rate, a blood pressure, a respiration rate, an electrocardiogram, a maximum oxygen intake, an arterial blood oxygen saturation, and a body temperature; The second biological information is a diagnosis of a disease of the user.

14. An inspection device according to any one of claims 1 to 13.

20. When the processor obtains a determination result indicating that the first biological information does not tend to be abnormal, the processor notifies the user of the result.

20. An inspection device according to any one of claims 1 to 19.

21. The processor obtains the determination result via wireless communication.

21. An inspection device according to any one of claims 1 to 20.

22. the determination result is derived by a measuring device attached to the user; The processor acquires the determination result from the measuring device.

22. An inspection device according to any one of claims 1 to 21.

23. the first biological information is measured a plurality of times by a measuring device attached to the user; The processor acquires a plurality of measurement results of the first biological information from the measurement device; Based on the results of a plurality of measurements of the first biological information obtained, it is determined whether the first biological information shows a tendency toward abnormality, and the determination result is obtained.

23. An inspection device according to any one of claims 1 to 22.

24. The measuring device is wearable 24. An inspection device according to claim 22 or 23.

25. If it is not possible to determine whether the first biological information is showing an abnormal tendency, The processor issues a notification to increase the wearing time of the measuring device.

25. An inspection device according to any one of claims 22 to 24.

26. The processor, Acquiring the second biometric information; A determination is made as to whether or not the measurement of the first biological information should be continued according to the acquired second biological information.

26. An inspection apparatus according to any one of claims 1 to 25.

27. The processor, after presenting the user with guidance corresponding to the selected test candidate, further presents guidance corresponding to another test candidate that performs a step-up test compared to the selected test candidate.

27. An inspection apparatus according to any one of claims 1 to 26.

Images